Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14123845 | 0.89 | TDP1 (0.54) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL13225165 | 0.88 | CASP2 (0.45) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL14117832 | 0.86 | TSHR (0.54) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL13498694 | 0.86 | TSHR (0.54) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL3486013 | 0.84 | ALDH1A1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL992117 | 0.84 | ALDH1A1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5490052 | 0.84 | ALDH1A1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL13936544 | 0.84 | MEN1 (0.46) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL13498696 | 0.84 | TDP1 (0.42) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL20158162 | 0.83 | EPHX2 (0.39) | TDP1CA1CA2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2086588-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008055972-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055972-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | PRLHR, GHRHR, TRHR | TDP1 3299/4885CA1 4864/4885CA2 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.